Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7567132 in Advanced Solid Tumors
NCT06537310Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2024
- Primary completion
- May 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, randomised, open-label trial of RO7567132 in solid tumor (2 arms), sponsored by Roche. Primary endpoints: Adverse Events at 27 months and Dose-limiting Toxicities at 3 weeks. Started Sep 2024; status: active, not recruiting.
02
Drugs
RO7567132
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06537310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06537310.